A second patient died in a late-stage trial of Zafgen Inc’s experimental obesity treatment, highlighting safety concerns associated with drugs that aim to treat a condition that affects one in three Americans. Shares of Zafgen tumbled more than 50 percent to $8.00 in premarket trading on Wednesday. The company said a patient receiving its drug, […]

Zafgen Inc said the U.S. Food and Drug Administration had put a late-stage trial of its obesity drug on partial hold, two days after the drug developer reported the death of a patient during the study. Zafgen’s stock was down about 24 percent at $15.92 in light premarket trading. Zafgen said it still expects to […]